Prescribing Odyssey in Psychiatry- A/ Prof Ajeet Singh

Posted on May 17, 2016

This clip opens with the controversial actions of 23andMe, a privately held personal genomics and biotechnology company based in California. In 2013, the FDA shut down and discontinued marketing of its personal genome service due to inaccurate health results being received and the acute adjustment reactions caused by such results. This is an excellent example of how companies should not proceed in this area.

‘The health care society must protect the vulnerable’

The hope for genetic prescribing is to screen out some of the trial and error involved with prescribing medication to clients. Dr Singh has termed the genomic variability in response to medication as the ‘Prescribing Odyssey’, where some clients may come into complete remission after 3 weeks, others will decline and some continuing along the same trajectory before the medication was introduced.

Time is money’ – the purpose of genetic prescribing is to reduce time and response remission. To save the time of the client and their families, the clinician and society as a whole. The hope is to save ‘costs’ and speed recovery. However, the science must be backed up by evidence.

‘What matters in functional recovery is remission’